Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment

Neurological Research

Volumn 32, Issue 2, 2010, Pages 157-165

  Fayed, Nicolás ^a   Dávila, Jorge ^a   Oliveros Jr , Antonio ^a   Medrano, Jaime ^a   Castillo, Julio ^a  

^a Division of Dermatology Quiron Hospital   (Spain)

Author keywords

Alzheimer's disease; Clinical dementia rating; Diffusion; Global deterioration scale; Magnetic resonance imaging; Mild cognitive impairment; Perfusion; Proton magnetic resonance spectroscopy; Single volume spectroscopy

Indexed keywords

CHOLINE; CREATININE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ALZHEIMER DISEASE; BRAIN; CLASSIFICATION; COGNITION DISORDERS; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77949461746     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X405164     Document Type: Article

References (54)

1. Welsh KA, Butters N, Hughes JP, et al. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1992; 49: 448-452
2. Morris RG. Recent developments in the neuropsychology of dementia. Int Rev Psychiatry 1994; 6: 85-107
3. Salmon E, Lespagnard S, Marique P, et al. Cerebral metabolic correlates of four dementia scales in Alzheimer's disease. J Neurol 2005; 252: 283-290
4. Reisberg B. Global measures: Utility in defining and measuring treatment response in dementia. Int Psychogeriatr 2007; 19: 421-456
5. Krishnan S, Talley BD, Slavin MJ, et al. Current status of functional MR imaging, perfusion-weighted imaging, and diffusion-tensor imaging in Alzheimer's disease diagnosis and research. Neuroimaging Clin North Am 2005; 15: 853-868
6. 1H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin North Am 2005; 15: 847-852
7. 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007; 28: 1330-1339
8. Speck O, Chang L, DeSilva NM, et al. Perfusion MRI of the human brain with dynamic susceptibility contrast: Gradient-echo versus spin-echo techniques. J Magn Reson Imaging 2000; 12: 381-387
9. Harris GJ, Lewis RF, Satlin A, et al. Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's. Am J Psychiatry 1996; 153: 721-724
10. 18F. AJNR Am J Neuroradiol 1995; 16: 1763-1770
11. Kantarci K, Jack CR Jr, Xu YC, et al. Mild cognitive impairment and Alzheimer disease: Regional diffusivity of water. Radiology 2001; 219: 101-107
12. Jagust WJ, Haan MN, Reed BR, et al. Brain perfusion imaging predicts survival in Alzheimer's disease. Neurology 1998; 51 (4): 1009-1013
13. Du AT, Jahng GH, Hayasaka S, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006; 67 (7): 1215-1220
14. Zhang Y, Schuff N, Jahng GH, et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007; 68 (1): 13-19
15. Stahl R, Dietrich O, Teipel SJ, et al. White matter damage in Alzheimer disease and mild cognitive impairment: Assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology 2007; 243 (2): 483-492.
16. Medina D, DeToledo-Morrell L, Urresta F, et al. White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging 2006; 27 (5): 663-672
17. Naggara O, Oppenheim C, Rieu D, et al. Diffusion tensor imaging in early Alzheimer's disease. Psychiatry Res 2006; 146 (3): 243-249
18. Bozzali M, Filippi M, Magnani G, et al. The contribution of voxelbased morphometry in staging patients with mild cognitive impairment. Neurology 2006; 67 (3): 453-460
19. Pennanen C, Testa C, Laakso MP, et al. A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry 2005; 76 (1): 11-14
20. Karas GB, Scheltens P, Rombouts SA, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage 2004; 23 (2): 708-716
21. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: Contribution of structural neuroimaging. Neuroimage 2003; 18 (2): 525-541
22. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005; 27 (12): 1863-1872
23. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22 (12): 1689-1707
24. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51 (6): 1546-1554
25. Roman GC, Tatemichi TK, Erkinjuntti et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Work Group. Neurology 1993; 43: 250-260
26. Widiger TA, Frances AJ, Pincus HA, et al. DSM-IV Sourcebook, Vol.IV, Washington, DC: American Psychiatric Association, 1998
27. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142
28. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 1990; 14: 538-546
29. Harris GJ, Lewis RF, Satlin A, et al. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: A promising alternative to nuclear medicine. AJNR Am J Neuroradiol 1998; 19: 1727-1732
30. Harris GJ, Pearlson GD. MRI-guided region of interest placement on emission computed tomograms. Psychiatry Res 1993; 50: 57-63
31. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain, Stuttgart: Thieme, 1988
32. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
33. Ousset PJ, Andrieu S, Reynish E, et al. [Clinical evaluation of dementia in a cohort of 358 patients with the French version of the Clinical Dementia Rating (CDR) scale]. Rev Med Interne 2003; 24: 283s-287s
34. Petersen RC, Thomas RG, Grundman M, et al. Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388
35. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
36. Gold G, Bouras C, Kö vari E, et al. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol 2000; 99: 579-582
37. Bradley KM, O'Sullivan VT, Soper ND, et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 2002; 125: 1772-1781
38. Braak H, Rub U, Schultz C, et al. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2006; 9: 35-44
39. Adalsteinsson E, Sullivan EV, Kleinhans N, et al. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000; 355: 1696-1697
40. Jessen F, Block W, Traber F, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001; 57: 930-932
41. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005; 162: 667-675
42. Modrego PJ, Pina MA, Fayed N, et al. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: A nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 2006; 20: 867-877
43. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145-155
44. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001; 15: 85-92
45. Wolf H, Jelic V, Gertz HJ, et al. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179: 52-76
46. Pearlson GD, Harris GJ, Powers RE, et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Arch Gen Psychiatry 1992; 49: 402-408
47. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-1113
48. Perneczky R, Hartmann J, Grimmer T, et al. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol 2007; 20: 84-88
49. Anderson VC, Litvack ZN, Kaye JA. Magnetic resonance approaches to brain aging and Alzheimer disease-associated neuropathology. Top Magn Reson Imaging 2005; 16: 439-452
50. Talbot PR, Lloyd JJ, Snowden JS, et al. Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia. Eur J Nucl Med 1994; 21: 503-508
51. 99mTc-HMPAO SPECT. Neuroradiology 1994; 36: 1-6
52. Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005; 64: 902-904
53. Hanyu H, Shindo H, Kakizaki D, et al. Increased water diffusion in cerebral white matter in Alzheimer's disease. Gerontology 1997; 43: 343-351
54. Sandson TA, Felician O, Edelman RR, et al. Diffusion-weighted magnetic resonance imaging in Alzheimer's disease. Diffusion-weighted magnetic resonance imaging in Alzheimer's disease. Dement Geriatr Cogn Disord 1999; 10: 166-171